Lorcaserin: A novel, selective 5-HT2C-receptor agonist for the treatment of obesity

Formulary

Volumn 45, Issue 6, 2010, Pages 180-186

  Pauli, Maribeth ^a   Abdelghany, Sam ^a  

^a YALE NEW HAVEN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEPRAMONE; LORCASERIN; MONOAMINE OXIDASE INHIBITOR; PHENTERMINE; PLACEBO; SEROTONIN 2C ANTAGONIST; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; TRIPTAN DERIVATIVE; ZONISAMIDE;

AGITATION; ANOREXIA; ANXIETY DISORDER; BODY COMPOSITION; BODY MASS; BORDERLINE HYPERTENSION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DEFECATION URGENCY; DIARRHEA; DIZZINESS; DRUG ACCUMULATION; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FECES INCONTINENCE; FLATULENCE; FOOD AND DRUG ADMINISTRATION; HEART PALPITATION; HEART VALVE REGURGITATION; HUMAN; HYPERTENSION; INSOMNIA; MAJOR DEPRESSION; METABOLIC ACIDOSIS; MOOD CHANGE; NAUSEA; OBESITY; PARESTHESIA; QUALITY OF LIFE; RESTLESSNESS; REVIEW; RHINOPHARYNGITIS; SEIZURE; SIDE EFFECT; SOMNOLENCE; STEATORRHEA; SUICIDAL IDEATION; SYNCOPE; TACHYCARDIA; TASTE DISORDER; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; VALVULAR HEART DISEASE; WEIGHT CONTROL; WEIGHT REDUCTION; XEROSTOMIA;

EID: 77958477594     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. World Health Organization: Obesity and Overweight fact sheet (No. 311). Avai lable at : http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed June 1, 2010.
2. Flega KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010;303:235-241.
3. Centers for Disease Control and Prevention. Overweight and Obesity. Available at: http://www.cdc.gov/obesity/. Accessed June 1, 2010.
4. United States Department of Health and Human Services. Of ce of the Surgeon General. The Surgeon General's call to action to prevent and decrease overweight and obesity. Available at: http://www.surgeongeneral.gov/topics/ obesity/. Accessed June 1, 2010.
5. National Institutes of Health; National Heart, Lung, and Blood Institute. Clinical guidelines on the identi cation, evaluation, and treatment of overweight and obesity in adults-the evidence report. Obes Res. 1998;6(Suppl 2): 51S-209S.
6. Huizinga MM. Weight-loss pharmacotherapy: a brief review. Clin Diabetes. 2007;25:135-140.
7. Halford JC, Harrold JA, Boyland EJ, Lawton CL, Blundell JE. Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs. 2007;67:27-55.
8. Smith SR, Prosser WA, Donahue DJ, Morgan ME, Anderson CM, Shanahan WR; APD356-004 Study Group. Lorcaserin (APD356), a selective 5-HT2C agonist, reduces body weight in obese men and women. Obesity. 2009;17:494-503.
9. Smith BM, Smith JM, Tsai JH, et al. Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity. J Med Chem. 2008;51:305-313.
10. Thomsen WJ, Grottick AJ, Menzaghi F, et al. Lorcaserin, a novel selective human 5-hydroxy-tryptamine2c agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther. 2008;325:577-587.
11. Zhao H, Guo Z. Medicinal chemistry strategies in follow-on drug discovery. Drug Discov Today. 2009;14:516-522.
12. Fletcher PJ, Tampakeras M, Sinyard J, Slassi A, Isaac M, Higgins GA. Characterizing the effects of 5-HT2c receptor ligands on motor activity and feeding behaviour in 5-HT2C receptor knockout mice. Neuropharma-cology. 2009;57:259-267.
13. Morgan M, Chen W, Anderson C, Prosser W, Donahue D, Shanahan W. Pharmacokinetic properties, metabolism and tolerability of lorca-serin in healthy volunteers. Paper presented at: Annual Meeting of The Obesity Society; Octo-ber 3-7, 2008; Phoenix, Ariz. Abstract 846-P.
14. Bays HE. Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease. Exp Rev Cardiovasc Ther. 2009;7:1429-1445.
15. Smith SR, Weissman NJ, Stubbe S, Anderson CM, Shanahan WR. Lorcaserin reduces body weight in obese and overweight subjects: Behavioral modication and Lorcaserin for Over-weight and Obesity Management, the BLOOM Trial. Poster presented at: American Diabetes Association's 19th Scienti c Sessions; June 5-9, 2009; New Orleans, La. Poster 96-LB.
16. Anderson CM. Lorcaserin hydrochloride - a novel 5-HT2c agonist for weight management. Paper presented at: 27th Annual Scienti c Meeting of The Obesity Society; October 24, 2009, Washington, DC.
17. Kaplan L. The BLOSSOM Trial: Ef cacy and safety of lorcaserin in obese and overweight men and women. Paper presented at: Annual Scientific Meeting of The Obesity Society; October 27, 2009; Washington, DC.
18. Clinical Trials. BLOOM-DM: behavioral modification and lorcaserin for overweight and obesity management in diabetes mellitus. Available at: http://clinicaltrials.gov. Accessed June 1, 2010.
19. Anderson CM, Smith SR, Sanchez M, Chuang E, Stubbe S, Shanahan WR. Long-term treatment with lorcaserin was not associated with depression or suicidal ideation in the BLOOM trial. Poster presented at: 27th Annual Scientific Meeting of The Obesity Society; October 25, 2009; Washington, DC. Poster 217-P.
20. HHS. FDA. FDA announces withdrawal fen-fluramine and dexfenfluramine (Fen-Phen). Available at: http://www.fda.gov/Drugs/Drug-Safety/ PostmarketDrugSafetyInformation-forPatientsandProviders/ucm179871.htm. Accessed June 1, 2010.
21. FDA. Guidance for industry developing products for weight management. February 2007. Available at: http://www.fda.gov/down-loads/Drugs/ GuidanceComplianceRegula-toryInformation/Guidances/ucm071612.pdf. Accessed June 1, 2010.
22. Cardinal Health website: http://www.cardinal.com. Accessed March 27, 2010.
23. Meridia [package insert]. North Chicago, IL: Abbott Laboratories, Inc., 2009.
24. Micromedex® Healthcare Series [intranet database]. Version 5.1. Greenwood Village, Colo.: Thomson Reuters (Healthcare) Inc